ArticleAnalytical and bioanalytical chemistry2025
Comprehensive chemical profiling and quality marker discovery in Shenxiao granules via orthogonal HILIC×RP 2D-LC/MS and mass defect filtering algorithm.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Shenxiao granules (SXG) are an effective traditional Chinese medicine (TCM) used in clinical settings in China for the treatment of diabetic nephropathy; however, the quality control of SXG faces several challenges due to its complex multi-herb composition and the wide polarity range of bioactive constituents. To address these challenges, we developed a novel and comprehensive analytical platform that integrated offline orthogonal HILIC×RP two-dimensional liquid chromatography (with a theoretical peak capacity of 7161), high-resolution quadrupole time-of-flight mass spectrometry, and a mass defect filtering (MDF)-based data acquisition algorithm. This strategy enabled the systematic characterization of 260 compounds, of which 36 were authenticated by standards, representing the most comprehensive chemical profile of SXG to date. Twelve critical quality markers (Q-markers) were further identified through a three-dimensional evaluation framework that encompasses pharmacopoeial compliance, pharmacological relevance to nephroprotection, and consensus fingerprint peaks. Rigorous validation demonstrated the method's robustness, with a relative standard deviation of less than 5% for precision, limits of detection ranging from 0.02 to 6.56 ng/mL, and recoveries between 84 and 119%. In conclusion, the established "multidimensional separation-computational annotation-hierarchical Q-marker screening" approach not only provides comprehensive chemical profiling and Q-marker discovery for SXG but also offers an excellent blueprint for the quality standardization of complex TCM formulations.
Indexed as
Identifiers
41254387What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.